[Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma]. 2016

Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
May 2020, Gan to kagaku ryoho. Cancer & chemotherapy,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
April 2009, Seminars in hematology,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
January 2016, Cancer treatment and research,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
April 2012, Nihon rinsho. Japanese journal of clinical medicine,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
August 2016, Haematologica,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
July 2020, Blood research,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
June 2003, Current treatment options in oncology,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
April 2016, Haematologica,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
January 2007, Hematology. American Society of Hematology. Education Program,
Hirokazu Murakami, and Takayuki Saitoh, and Tetsuhiro Kasamatsu
January 2015, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!